Literature DB >> 1445274

Immunological detection of degradation intermediates of skeletal-muscle glycogen phosphorylase in vitro and in vivo.

E J Cookson1, A V Flannery, J A Cidlowski, R J Beynon.   

Abstract

Over 95% of the pyridoxal phosphate (PLP) in skeletal is bound to one protein, glycogen phosphorylase. This, and the fact that phosphorylase constitutes approx. 5% of the soluble protein in skeletal muscle, introduce the possibility that PLP might be used as a specific label to identify degradation intermediates of the enzyme. In this investigation, we have developed immunological methods, using a monoclonal antibody to PLP and polyclonal antibodies to phosphorylase, to detect degradation intermediates in vitro and in vivo. We have identified a family of degradation intermediates of glycogen phosphorylase in the high-speed-supernatant fraction of mouse skeletal muscle. These peptides react with both types of antibodies and are in the size and concentration range expected for degradation intermediates in a model in which the committed step is followed by rapid clearance of the products. Changes in amounts of degradation intermediates are examined in physiological or pathological conditions in which the rate of degradation of phosphorylase is altered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445274      PMCID: PMC1132112          DOI: 10.1042/bj2880291

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  Effect of denervation on the expression of glycogen phosphorylase in mouse skeletal muscle.

Authors:  D M Leyland; P C Turner; R J Beynon
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

2.  The expression of glycogen phosphorylase in normal and dystrophic muscle.

Authors:  D M Leyland; R J Beynon
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

3.  Purification and identification of intermediate catabolic products in the in vivo degradation of pig liver phosphofructokinase.

Authors:  T Toda; M Ohashi
Journal:  J Biol Chem       Date:  1986-09-25       Impact factor: 5.157

4.  Analysis of bacteriophage T7 early RNAs and proteins on slab gels.

Authors:  F W Studier
Journal:  J Mol Biol       Date:  1973-09-15       Impact factor: 5.469

5.  Identification of intracellular degradation intermediates of aldolase B by antiserum to the denatured enzyme.

Authors:  A Z Reznick; L Rosenfelder; S Shpund; D Gershon
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

6.  A semicontinuous assay for glycogen phosphorylase.

Authors:  I T Carney; R J Beynon; J Kay; N Birket
Journal:  Anal Biochem       Date:  1978-03       Impact factor: 3.365

7.  The structure of glycogen phosphorylase alpha at 2.5 A resolution.

Authors:  S Sprang; R J Fletterick
Journal:  J Mol Biol       Date:  1979-07-05       Impact factor: 5.469

8.  Degradation artefacts during sample preparation for sodium dodecyl sulphate polyacrylamide gel electrophoresis.

Authors:  E J Cookson; R J Beynon
Journal:  Biosci Rep       Date:  1987-03       Impact factor: 3.840

9.  Limited proteolysis of enzymes: the generation of functionally modified derivatives in vitro and in vivo.

Authors:  R J Beynon; G A Place; P E Butler
Journal:  Biochem Soc Trans       Date:  1985-04       Impact factor: 5.407

10.  Degradation of oxidized insulin B chain by the multiproteinase complex macropain (proteasome).

Authors:  L R Dick; C R Moomaw; G N DeMartino; C A Slaughter
Journal:  Biochemistry       Date:  1991-03-12       Impact factor: 3.162

View more
  2 in total

Review 1.  Proteome dynamics: revisiting turnover with a global perspective.

Authors:  Amy J Claydon; Robert Beynon
Journal:  Mol Cell Proteomics       Date:  2012-11-02       Impact factor: 5.911

2.  Renal expression of the brain and muscle isoforms of glycogen phosphorylase in different cell types.

Authors:  Heide Schmid; Benedikt Dolderer; Ulrike Thiess; Stephan Verleysdonk; Bernd Hamprecht
Journal:  Neurochem Res       Date:  2008-03-13       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.